KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced ...
9don MSN
Recursion eyes breakthrough with REC-4881 drug for rare genetic condition, but shares pull back
Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early ...
Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion believes that these new libraries will be of interest to customers given the additional predictive insights via MatchMaker. The tool employs machine learning to evaluate the suitability of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results